申请人:Sunovion Pharmaceuticals Inc.
公开号:US11186564B2
公开(公告)日:2021-11-30
Compounds of formula I:
are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
式 I 的化合物:
以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状,如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍,以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。